TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
January 14, 2009

#### FORM 6-K

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer** 

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of January 2009

Commission File Number \_\_\_\_\_\_0-16174

\_\_1\_\_

Teva Pharmaceutical Industries Limited
(Translation of registrant's name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes NoX
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):
82

Website: www.tevapharm.com	Website:	www.tevan	harm.com
----------------------------	----------	-----------	----------

Contact: Elana Holzman Teva Pharmaceutical Industries Ltd. 972 (3) 926-7554

Kevin Mannix Teva North America (215) 591-8912

#### WEBCAST ALERT - FOR IMMEDIATE RELEASE

TEVA TO PRESENT AT THE GOLDMAN SACHS

Healthcare CEOs Unscripted conference

**Jerusalem, Israel, January 7, 2009** - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference in New York. William Marth, President and CEO, Teva North America, will present on Thursday, January 8, 2009.

What: Teva Presentation at the Goldman Sachs Healthcare CEOs Unscripted

Conference in New York

Who: William Marth, President and CEO, Teva North America

When: Thursday, January 8, 2009 at 10:45 a.m. ET

Where: www.tevapharm.com or

http://cc.talkpoint.com/GOLD006/010709a mg/?entity=tevausa

<b>How:</b> Live over the Internet log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.
Teva Pharmaceutical Industries Ltd. Web Site: <a href="www.tevapharm.com">www.tevapharm.com</a>

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchang	e Act of 1934,	the registrant has duly	caused this report to be
signed on its behalf by the undersigned, thereunto duly	authorized.		

### TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: <u>/s/ Eyal Desheh</u>

Name: Eyal Desheh

Title: Chief Financial Officer

Date: January 7, 2009

\_\_2\_\_